Cancer Therapy & Radiation Oncology

Advances in Stereotactic Body Radiation Therapy (SBRT)

Stereotactic Body Radiation Therapy has emerged as a highly precise and effective modality for delivering ablative radiation doses to extracranial tumors in limited fractions. Technological improvements in imaging guidance, motion tracking, and dose calculation algorithms have expanded SBRT applications across lung, liver, spine, pancreas, and prostate malignancies. The ability to deliver high biologically effective doses with sub-millimeter accuracy has demonstrated excellent local control rates while preserving surrounding normal tissues. Advances in respiratory gating and real-time tumor tracking further reduce uncertainties related to organ motion. Clinical trials continue to refine dose constraints, fractionation schedules, and patient selection criteria. SBRT is increasingly used in oligometastatic disease, offering curative-intent therapy in carefully selected patients. Integration with systemic therapies and immunotherapy is an active area of research, exploring potential synergistic benefits. Technological platforms such as robotic radiosurgery systems enhance flexibility in complex anatomical sites. Radiobiological insights into hypofractionation mechanisms support its expanding indications. Long-term toxicity data are guiding safety optimization and protocol standardization. SBRT contributes to shorter treatment courses, improved patient convenience, and reduced healthcare burden. Its role in early-stage inoperable cancers and metastatic settings underscores its transformative impact on contemporary radiation oncology practice worldwide.